71-33-0|1,3,5-Triazine-2,4(1H,3H)-dione| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 71-33-0 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 71-33-0 ]

CAS No. :	71-33-0
Formula :	C₃H₃N₃O₂
M.W :	113.07
SMILES Code :	O=C(N1)NC=NC1=O
MDL No. :	MFCD00023157
InChI Key :	GEWRKGDRYZIFNP-UHFFFAOYSA-N
Pubchem ID :	6275

Safety of [ 71-33-0 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

Computational Chemistry of [ 71-33-0 ] Show Less

Physicochemical Properties

Num. heavy atoms	8
Num. arom. heavy atoms	6
Fraction Csp3	0.0
Num. rotatable bonds	0
Num. H-bond acceptors	3.0
Num. H-bond donors	2.0
Molar Refractivity	25.48
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	78.61 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	-0.12
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	-1.87
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	-1.54
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-1.68
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.11
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	-0.82

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	0.08
Solubility	137.0 mg/ml ; 1.21 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Highly soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	0.74
Solubility	619.0 mg/ml ; 5.48 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Highly soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.04
Solubility	10.4 mg/ml ; 0.092 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-8.32 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	2.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.4

Application In Synthesis of [ 71-33-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 71-33-0 ]

[ 71-33-0 ] Synthesis Path-Downstream 1~35

1
[ 186581-53-3 ]
[ 71-33-0 ]
[ 873-48-3 ]

References: [1]Collection of Czechoslovak Chemical Communications,1961,vol. 26,p. 2519 - 2528.

2
[ 71-33-0 ]
[ 27032-78-6 ]

References: [1]Collection of Czechoslovak Chemical Communications,1961,vol. 26,p. 2519 - 2528.
[2]Journal of the American Chemical Society,1955,vol. 77,p. 1051.

3
[ 1898-72-2 ]
[ 71-33-0 ]

References: [1]Helvetica Chimica Acta,1959,vol. 42,p. 485 - 489.

4
[ 122-51-0 ]
[ 57-13-6 ]
[ 71-33-0 ]

References: [1]Collection of Czechoslovak Chemical Communications,1963,vol. 28,p. 2376,2379.

5
[ 186581-53-3 ]
[ 67-56-1 ]
[ 71-33-0 ]
[ 89532-11-6 ]

References: [1]Collection of Czechoslovak Chemical Communications,1963,vol. 28,p. 2365 - 2374.

6
[ 71-33-0 ]
[ 2831-66-5 ]

References: [1]Agricultural and Biological Chemistry,1982,vol. 46,p. 1439 - 1445.

Yield	Reaction Conditions	Operation in experiment
48%		A solution of sodium methoxide in methanol (2.17M-2.76 ml; 6 mmol) was added to a suspension of the urea (Intermediate 29, 700 mg; 2 mmol) in methanol (10 ml) at 23. The mixture was stirred under nitrogen for 1.5 h then poured into 15% phosphate buffer solution (200 ml) and extracted with chloroform (3*100 ml) and ethyl acetate (100 ml). The combined, dried extracts were evaporated and the residue triturated with ethyl acetate to give the triazinedione (305 mg; 48%) as a cream solid with m.p. >250.
		d. 4-Dimethylamino-1-ethyl-1,3,5-triazine-2,6-dione. The triazinone from (c) (0.5 g) was heated in an oil bath at 220 C for 10 minutes. The cooled product was recrystallized from ethanol to give the triazine-dione having a melting point of 233-235 C (decomp.).
		Among the compounds of formula (II), mention may be made especially of the following preferred compounds: parabanic acid ... 1-methyluracil 3-methyluracil 5-methyluracil 1,3-dimethyluracil 5-azauracil 6-azauracil 5-fluorouracil 6-fluorouracil ...

10
silver-salt of/the/ 4,6-dioxo-1,4,5,6-tetrahydro-<1,3,5>triazine-2-carboxylic acid [ No CAS ]
[ 71-33-0 ]

References: [1]Journal of the American Chemical Society,1955,vol. 77,p. 1051.

11
[ 71-33-0 ]
[ 7732-18-5 ]
sodium-amalgam [ No CAS ]
acid [ No CAS ]
[ 27032-78-6 ]

References: [1]Journal of the American Chemical Society,1955,vol. 77,p. 1051.

12
[ 71-33-0 ]
[ 108-13-4 ]
1,2,3,4,5,6-hexahydro-6-(dicarbamoylmethyl)-1,3,5-triazine-2,4-dione [ No CAS ]

References: [1]Mendeleev Communications,2001,vol. 11,p. 234 - 235.
[2]Pharmaceutical Chemistry Journal,2002,vol. 36,p. 146 - 150.

13
[ 71-33-0 ]
[ 95-54-5 ]
1,2,3,4,5,6-hexahydro-6-(3',4'-diaminophenyl)-1,3,5-triazine-2,4-dione [ No CAS ]

References: [1]Mendeleev Communications,2001,vol. 11,p. 234 - 235.

14
[ 71-33-0 ]
[ 2829-26-7 ]
6-(4-{N'-[1-(4-Chloro-phenyl)-meth-(E)-ylidene]-hydrazino}-phenyl)-[1,3,5]triazinane-2,4-dione [ No CAS ]

References: [1]Mendeleev Communications,2001,vol. 11,p. 234 - 235.

15
[ 71-33-0 ]
[ 2829-27-8 ]
6-(4-{N'-[1-(4-Nitro-phenyl)-meth-(E)-ylidene]-hydrazino}-phenyl)-[1,3,5]triazinane-2,4-dione [ No CAS ]

References: [1]Mendeleev Communications,2001,vol. 11,p. 234 - 235.

16
[ 71-33-0 ]
[ 108-46-3 ]
2,4-bis(1',2',3',4',5',6'-hexahydro-1',3',5'-triazine-2',4'-dion-6'-yl)-1,5-dioxybenzene [ No CAS ]

References: [1]Pharmaceutical Chemistry Journal,2002,vol. 36,p. 146 - 150.
[2]Mendeleev Communications,2001,vol. 11,p. 234 - 235.

17
[ 71-33-0 ]
[ 87-66-1 ]
1,2,3,4,5,6-hexahydro-6-(2',3',4'-trihydroxyphenyl)-1,3,5-triazine-2,4-dione [ No CAS ]

References: [1]Mendeleev Communications,2001,vol. 11,p. 234 - 235.

18
[ 71-33-0 ]
[ 622-73-1 ]
6-(4-{N'-[1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-hydrazino}-phenyl)-[1,3,5]triazinane-2,4-dione [ No CAS ]

References: [1]Mendeleev Communications,2001,vol. 11,p. 234 - 235.

19
[ 71-33-0 ]
[ 89-25-8 ]
[ 108-19-0 ]
[ 61466-03-3 ]

References: [1]Pharmaceutical Chemistry Journal,2002,vol. 36,p. 146 - 150.

20
[ 71-33-0 ]
[ 4845-49-2 ]
[ 108-19-0 ]
[ 58376-76-4 ]

References: [1]Pharmaceutical Chemistry Journal,2002,vol. 36,p. 146 - 150.

21
[ 71-33-0 ]
[ 6402-09-1 ]
[ 108-19-0 ]
4-[1-[5-Hydroxy-3-methyl-1-(4-nitro-phenyl)-1H-pyrazol-4-yl]-meth-(Z)-ylidene]-5-methyl-2-(4-nitro-phenyl)-2,4-dihydro-pyrazol-3-one [ No CAS ]

References: [1]Pharmaceutical Chemistry Journal,2002,vol. 36,p. 146 - 150.

22
[ 71-33-0 ]
[ 34320-83-7 ]
[ 108-19-0 ]
4-[1-[5-Hydroxy-3-(4-nitro-phenyl)-1-phenyl-1H-pyrazol-4-yl]-meth-(Z)-ylidene]-5-(4-nitro-phenyl)-2-phenyl-2,4-dihydro-pyrazol-3-one [ No CAS ]

References: [1]Pharmaceutical Chemistry Journal,2002,vol. 36,p. 146 - 150.

23
[ 71-33-0 ]
[ 89-25-8 ]
[ 61466-03-3 ]

References: [1]Chemistry of Heterocyclic Compounds,2003,vol. 39,p. 1478 - 1486.

24
[ 27738-96-1 ]
[ 71-33-0 ]

Yield	Reaction Conditions	Operation in experiment
	With trifluoroacetic acid; In tetrahydrofuran; dichloromethane;	Step 8 The Formation of 1,3,5-Triazine-2,4-dione The resin (200 mg, 0.22 mmol; loading 1.1 mmol/g) obtained from step 7 was swollen in anhydrous THF (4 ml), (70.8 mul, 0.88 mmol) of chlorocarbonylisocyanate was subsequently added. This reaction was allowed to shake at room temperature for 2 hrs. The mixture was filtered and the resin was washed with THF (34 ml), CH2Cl2 (34 ml), and dried. To confirm that the reaction occured, 100 mg of resin was treated with 50% TFA/CH2Cl2 for 1 hr, filtered, and the filtrate was concentrated. LC/MS analysis, showed correct M++H, 317. 1H NMR (DMSO-d6) delta 1.21 (m, 4H), 1.38-1.40 (m, 2H), 3.10-3.14 (m, 4H), 7.57 (d, 2H), 8.03 (d, 2H), 11.10 (s, 1H), 13.15 (s, 1H).

References: [1]Patent: US2002/49320,2002,A1 .

25
[ 71-33-0 ]
[ 2374-27-8 ]
[ 120315-29-9 ]

References: [1]Zeitschrift fur Naturforschung, B: Chemical Sciences,1987,vol. 42,p. 1556 - 1562.

26
[ 71-33-0 ]
[ 2374-27-8 ]
{(CH₃Hg)3C₃HN₃O₂}⁽¹⁺⁾*NO₃^(1-)={(CH₃Hg)3C₃HN₃O₂}NO₃ [ No CAS ]

References: [1]Zeitschrift fur Naturforschung, B: Chemical Sciences,1987,vol. 42,p. 1556 - 1562.

27
[ 71-33-0 ]
[ 108-86-1 ]
[ 234772-19-1 ]